Study on Androgen Receptor and Triple Negative Breast Cancer
NCT03383679
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
94
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer Female
Triple Negative and Androgen Receptor Positive
Interventions
DRUG:
Darolutamide
DRUG:
Capecitabine
Sponsor
UNICANCER